Quantcast

Latest Bristol-Myers Squibb Stories

2014-08-15 12:25:07

ATLANTA, Aug. 15, 2014 /PRNewswire/ -- Avion Pharmaceuticals, LLC, announces the signing of a commercial license agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) for the development and commercialization of four Captisol-enabled programs. Under the terms of the agreement, Ligand is entitled to receive an up-front payment, and is eligible to receive revenue from Captisol® material sales, potential milestone payments, and royalties on future net sales of the products...

2014-08-12 16:27:31

DUBLIN, Aug. 12, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Biological drugs are typically derived from living cells and are used in the treatment and prevention of various diseases such as cancer, blood-related diseases, auto-immune diseases and other medical disorders....

2014-08-07 12:28:07

NUSSLOCH, Germany, August 7, 2014 /PRNewswire/ -- - Leica Biosystems announces a collaboration with Bristol-Myers Squibb to develop companion diagnostic tests in support of targeted therapeutics - Leica Biosystems will develop fully automated tissue-based companion diagnostic tests to run on the BOND(TM) automated advanced staining systems Leica Biosystems, today announced an agreement with Bristol-Myers Squibb Company (NYSE:...

2014-07-31 16:27:33

OTTAWA, July 31, 2014 /CNW/ - Health Canada today released the July 2014 issue of the Canadian Adverse Reaction Newsletter (CARN). This issue includes an article on the anti-cancer drug cisplatin and the risk of blockage of the aorta, the body's main artery. It also includes an article on hydroxychloroquine, a drug used for rheumatoid arthritis, lupus, and malaria, and the risk of developing low blood sugar; and a case presentation on a suspected interaction between efavirenz, an...

2014-07-24 16:27:06

Global BioPharmaceutical Leader Leases an Additional 61,000 Square Feet to Grow Its Presence and Research Capabilities in the Bay Area SAN DIEGO, July 24, 2014 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that Bristol-Myers Squibb (NYSE: BMY) has signed a ten-year lease for approximately 61,000 square feet of additional laboratory and office space at the company's Woodside Technology Park life science campus in Redwood City, California. The Redwood City...

2014-07-10 12:34:44

CLARK, N.J., July 10, 2014 /PRNewswire/ -- GEP, a leading provider of procurement and supply chain solutions to Fortune 500 and Global 2000 enterprises worldwide, is pleased to announce that it has been selected by global biopharmaceuticals leader Bristol-Myers Squibb (NYSE: BMY) to provide procurement services under a multiyear agreement. GEP will help Bristol-Myers Squibb identify cost savings opportunities from its global spending. "We're delighted to have been selected by...

2014-07-07 23:06:26

On July 1, the FDA published that 6 lots of Coumadin (Warfarin Sodium) for Injection, 5 mg single-use vials, by Bristol-Myers Squibb, are recalled due to the presence of visible particulate matter. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) July 07, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on...

2014-07-01 16:25:46

LONDON, July 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Bristol-Myers Squibb Company - Product Pipeline Review - 2014http://www.reportbuyer.com/pharma_healthcare/therapeutic/bristol_myers_squibb_company_product_pipeline_review_2013.html Bristol-Myers Squibb Company - Product Pipeline Review - 2014 SummaryGlobal Markets Direct's, 'Bristol-Myers Squibb Company - Product Pipeline Review - 2014', provides an overview of the Bristol-Myers Squibb...

2014-06-30 13:06:13

European Society for Medical Oncology ESMO 16 World GI Congress on Gastrointestinal Cancer The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. "Around 50% of patients with colorectal cancer develop metastases but eventually many of them do not respond to standard therapies,"...

2014-06-30 12:40:20

European Society for Medical Oncology ESMO 16 World GI Congress on Gastrointestinal Cancer For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. "The CALGB/SWOG 80405 trial was designed and formulated in 2005, and the rationale was simple: we had new drugs --bevacizumab and cetuximab-- and the study...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related